Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism

Neuropsychiatric Disease and Treatment

Volumn 6, Issue 1, 2010, Pages 37-46

  Azorin, Jean Michel ^a   Bowden, Charles L ^b   Garay, Ricardo P ^c   Perugi, Giulio ^d   Vieta, Eduard ^e   Young, Allan H ^f  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c CNRS   (France)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alcohol; Alcoholism; Bipolar disease; Comorbidity; Valproate

Indexed keywords

ACAMPROSATE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; GABAPENTIN; GAMMA GLUTAMYLTRANSFERASE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPAM; PLACEBO; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROIC ACID;

ACUTE ALCOHOL HALLUCINOSIS; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL TRIAL; COMORBIDITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EFFECT SIZE; HALLUCINOSIS; HUMAN; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; QUALITY OF LIFE; REVIEW; SIDE EFFECT;

EID: 77950792021     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Frye MA, Salloum IM. Bipolar disorder and comorbid alcoholism: prevalence rate and treatment considerations. Bipolar Disord. 2006;8:677-685.
2. Vornik LA, Brown ES. Management of comorbid bipolar disorder and substance abuse. J Clin Psychiatry. 2006;67:24-30.
3. Brown ES. Management of comorbid bipolar disorder and substance abuse. J Clin Psychiatry. 2006;67(Suppl 7):24-30.
4. Weiss RD. Treating patients with bipolar disorder and substance dependence: Lessons learned. J Subst Abuse Treat. 2004;27: 307-312.
5. Weiss RD, Griffin ML, Jaffee WB, et al. A "community-friendly" version of integrated group therapy for patients with bipolar disorder and substance dependence: A randomized controlled trial. Drug Alcohol Depend. 2009;104:212-219.
6. Farren CK, McElroy S. Treatment response of bipolar and unipolar alcoholics to an inpatient dual diagnosis program. J Affect Disord. 2008;106:265-272.
7. Lan MJ, McLoughlin GA, Griffin JL, et al. Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol Psychiatry. 2008;14:269-279.
8. Kato T. Molecular neurobiology of bipolar disorder: a disease of 'mood-stabilizing neurons'? Trends Neurosci. 2008;31:495-503.
9. Catapano LA, Manji HK. G protein-coupled receptors in major psychiatric disorders. Biochim Biophys Acta. 2007;1768:976-993.
10. Geller B, Cooper TB, Sun K, et al. Double blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry. 1998;37:171-178.
11. Brady KT, Sonne SC. The relationship between substance abuse and bipolar disorder. J Clin Psychiatry. 1995;56(Suppl 3):19-24.
12. Brady KT, Sonne SC, Anton R, Ballenger JC. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry. 1995;56:118-121.
13. Brady KT, Myrick H, Henderson S, Coffey SF. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. 2002;67:323-330.
14. Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2005;62:37-45.
15. American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders, 2nd edition. 2006. Available from: http://wwwpsychorg/psych_pract/treatg/pg/prac_guide.cfm. Accessed on August 10, 2009.
16. Sattar SP. Valproate in the treatment of bipolar disorder and co-morbid substance abuse: a 24-week open lable trial. Biol Psychiatry. 2007;61:46S.
17. Reoux JP, Malte CA, Farr CL, Ferguson LC, Saxon AJ, editors. Controlled trial of extended release divalproex sodium in alcohol dependent patients with subsyndromal psychiatric symptoms. 18Th annual meeting and symposium of the American Academy of Addiction Psychiatry (AAAP); 2007; Hotel Del Coronado, Coronado, CA, USA.
18. Bryant AE III, Dreifuss FE. Valproic acid hepatic fatalities. III. US experience since 1986. Neurology. 1996;46:465-469.
19. Jimenez-Rodriguezvila M, Caro-Patón A, Conde M, et al. Side-effects of sodium valproate, mainly related to its hepatic and pancreatic toxicity. Int J Clin Pharmacol Res. 1986;6:217-224.
20. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology. 1987;37:379-385.
21. Dreifuss FE, Langer DH. Hepatic considerations in the use of antiepileptic drugs. Epilepsia. 1987;28(Suppl 2):S23-S29.
22. Rubio G, López-Muñoz F, Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord. 2006;8:283-293.
23. Guille C, Sachs G. Clinical outcome of adjunctive topiramate treatment in a sample of refractory bipolar patients with comorbid conditions. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:1035-1039.
24. Huguelet P, Morand-Collomb S. Effect of topiramate augmentation on two patients suffering from schizophrenia or bipolar disorder with comorbid alcohol abuse. Pharmacol Res. 2005;52:392-394.
25. Perugi G, Toni C, Frare F, et al. Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? J Clin Psychopharmacol. 2002;22:584-591.
26. Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2007;9:413-425.
27. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351-1360.
28. Thase ME, Macfadden W, Weisler RH, et al; BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26:600-609.
29. Longoria J, Brown ES, Perantie DC, Bobadilla L, Nejtek VA. Quetiapine for alcohol use and craving in bipolar disorder. J Clin Psychopharmacol. 2004;24:101-102.
30. Brown ES, Nejtek VA, Perantie DC, Bobadilla L. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord. 2002;4:406-411.
31. Brown ES, Nejtek VA, Perantie DC, Rajan Thomas N, Rush AJ. Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol. 2003;23:384-388.
32. Sattar SP, Schultz SK, Arndt S, Soundy T, Petty F. Long-term adjunctive quetiapine may reduce substance use-a preliminary retrospective study. South Dakota Med. 2007;60:439-441.
33. Brown ES, Garza M, Carmody TJ. A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders. J Clin Psychiatry. 2008;69: 701-705.
34. Martinotti G, Andreoli S, Di Nicola M, Di Giannantonio M, Sarchiapone M, Janiri L. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Human Psychopharmacol Clin Exp. 2008;23:417-424.
35. Brown ES, Jeffress J, Liggin JD, Garza M, Beard L. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry. 2005;66:756-760.
36. Davis LL, Li X, Garner C, Biladeau J, Ustinov Y, Uezato A. Divalproex ER versus risperidone for bipolar disorder with comorbid substance use disorder. Washington, DC: 161st Annual Meeting of the American Psychiatric Association; May 3-8, 2008.
37. Frye MA, Chirichigno JW, McKowen J, et al. A single-blind evaluation of divalproex sodium vs olanzapine for alcohol abuse relapse prevention in bipolar disorder. Don Cesar Beach Resort, FL: AAAP Annual Meeting and Symposium Dec 7-10, 2006.
38. Brown ES, Beard L, Dobbs L, Rush AJ. Naltrexone in patients with bipolar disorder and alcohol dependence. Depress Anxiety. 2006;23:492-495.
39. Salloum IM, Douaihy A, Cornelius JR, Daley DC, Kelly TM, Kirisci L. Open label randomized pilot study of combined naltrexone and valproate in bipolar alcoholics. Alcohol Clin Exp Res. 2006;30:140A.
40. Reoux JP, Saxon AJ, Malte CA, Baer JS, Sloan KL. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res. 2001;25:1324-1329.
41. Longo LP, Campbell T, Hubatch S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis. 2002; 21:55-64.
42. Aliyev ZN, Aliyev NA. Valproate treatment of acute alcohol hallucinosis: a double-blind, placebo-controlled study. Alcohol Alcohol. 2008;43:456-459.
43. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298:1641-1651.
44. Johnson BA, Rosenthal N, Capece JA, et al; Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med. 2008;168:1188-1199.
45. Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord. 2006;8:15-27.
46. Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68:1691-1700.
47. Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm. 2003;9:559-568.
48. Martinotti G, Di Nicola M, Di Giannantonio M, Janiri L. Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs naltrexone. J Psychopharmacol. 2009;23:123-129.
49. Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008;28:5-12.
50. Dorus W, Ostrow DG, Anton R, et al. Lithium treatment of depressed and nondepressed alcoholics. JAMA. 1989;262:1646-1652.
51. Dilsaver SC, Swann AC, Shoaib AM, Bowers TC. The manic syndrome: factors which may predict a patient's response to lithium, carbamazepine and valproate. J Psychiatry Neurosci. 1993;18:61-66.
52. Petty F. GABA and mood disorders: a brief review and hypothesis. J Affective Disord. 1995;34:275-281.
53. Brambilla P, Perez J, Barale F, Schettini G, Soares JC. GABAergic dysfunction in mood disorders. Mol Psychiatry. 8:721-737.
54. Enoch MA. The role of GABAa receptors in the development of alcoholism. Pharmacol Biochem Behav. 2008;90:95-104.
55. Vargas C, Tannhauser M, Barros HM. Dissimilar effects of lithium and valproic acid on GABA and glutamine concentrations in rat cerebrospinal fluid. Gen Pharmacol. 1998;30:601-604.
56. Zimmer R, Teelken AW, Gündürewa M, Rüther E, Cramer H. Effect of sodium-valproate on CSF GABA, cAMP, cGMP and homovanillic acid levels in men. Br Res Bull. 1980;5(Suppl 2):585-588.
57. Pacchiarotti I, Marzo SD, Colom F, Sanchez-Moreno J, Vieta E. Bipolar disorder preceded by substance abuse: A different phenotype with not so poor outcome? World J Biol Psychiatry. 2007;13:1-8.
58. Haro JM, van Os J, Vieta E, Reed C, Lorenzo M, Goetz I; EMBLEM Advisory Board. Evidence for three distinct classes of 'typical', 'psychotic' and 'dual' mania: results from the EMBLEM study. Acta Psychiatr Scand. 2006;113:112-120.
59. van Rossum I, Haro JM, Tenback D, et al. Stability and treatment outcome of distinct classes of mania. Eur Psychiatry. 2008;23:360-367.
60. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64:543-552.
61. Merikangas KR, Herrell R, Swendsen J, Rössler W, Ajdacic-Gross V, Angst J. Specificity of bipolar spectrum conditions in the comorbidity of mood and substance use disorders: results from the Zurich cohort study. Arch Gen Psychiatry. 2008;65:47-52.
62. Albanese MJ, Clodfelter RC Jr, Pardo TB, Ghaemi SN. Underdiagnosis of bipolar disorder in men with substance use disorder. J Psychiatr Pract. 2006;12:124-127.
63. Brousse G, Garay RP, Benyamina A. Management of comorbid bipolar disorder and alcohol dependence. Presse Med. 2008;37:1132-1137.